COVID-19 infections impact cardiovascular disease

The full impact of COVID-19 infections, even mild and moderate cases, is still being understood. And now, recent research has revealed that the medium and long-term impact of an acute illness may be associated with cardiovascular events, such as venous thromboembolism, stroke and myocardial infarction.

U.K.-based researchers examined more than 20,000 participants from the UK Biobank who had recorded COVID-19 infection status. The UK Biobank is a large cohort of middle-aged volunteers recruited between 2006 and 2010. Researchers published their findings in Heart.

The analysis found that of the patients with confirmed COVID-19, 80% did not require hospitalization. In 9% of cases, compared to 0.7% of control subjects, evidence of at least one incident of myocardial infarction, stroke, heart failure, atrial fibrillation, venous thromboembolism, pericarditis, cardiovascular mortality, ischaemic heart disease mortality and all-cause mortality was recorded. Cardiovascular events were 3% more frequent in those with compared to those without (0.5%) confirmed COVID-19 infection.

“In those hospitalized with COVID-19 as a primary illness, the risk of venous thromboembolism, heart failure, stroke and myocardial infarction were markedly elevated,” wrote first author Anda Bularga, of the Centre for Cardiovascular Science, University of Edinburgh, Edinburgh, U.K., et al.

In addition, there was a vast excess of mortality in all groups with COVID-19, and it was the greatest among those hospitalized with COVID-19 as a primary or secondary diagnosis compared to those who were not admitted. Researchers also found that cardiovascular risks were greatest in the first 30 days after infection, but remained higher than controls after that initial 30-day period. 

The study adds to the ongoing dialogue about the long-term impact of a COVID-19 infection. The findings underscore the potential need for greater attention to management of cardiovascular risk and a low threshold for cardiovascular investigations of patients exposed to COVID-19 for prevention and timely treatment of cardiovascular events.

Amy Baxter

Amy joined TriMed Media as a Senior Writer for HealthExec after covering home care for three years. When not writing about all things healthcare, she fulfills her lifelong dream of becoming a pirate by sailing in regattas and enjoying rum. Fun fact: she sailed 333 miles across Lake Michigan in the Chicago Yacht Club "Race to Mackinac."

Around the web

The final list also included diabetes drugs sold by Boehringer Ingelheim and Merck. The first round of drug price negotiations reduced the Medicare prices for 10 popular drugs by up to 79%. 

HHS has thought through the ways AI can and should become an integral part of healthcare, human services and public health. Last Friday—possibly just days ahead of seating a new secretary—the agency released a detailed plan for getting there from here.

Philips is recalling the software associated with its Mobile Cardiac Outpatient Telemetry devices after certain high-risk ECG events were never routed to trained cardiology technicians as intended. The issue, which lasted for two years, has been linked to more than 100 injuries.